[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100270849":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":7,"locations":13,"responsibleParty":48,"collaborators":7,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":7,"enrollmentInfo":60,"targetDuration":7,"studyType":63,"phases":7,"briefSummary":64,"conditions":65,"keywords":7,"overallStatus":67,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Tarek M. Fiad, MBBCH MD FRCPI FRCP","Endocrinology Division Departemnt of Medicine, SKMC-UAE","PRINCIPAL_INVESTIGATOR",[14,25,34,41],{"facility":15,"status":7,"city":16,"state":7,"zip":7,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":7},"Research Site","Kuwait City","Kuwait","KW",{"type":20,"coordinates":21},"Point",[22,23],47.97429,29.367,{"lat":23,"lon":22},{"facility":15,"status":7,"city":26,"state":7,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":33,"contacts":7},"Abu Dhabi","United Arab Emirates","AE",{"type":20,"coordinates":30},[31,32],54.39696,24.45118,{"lat":32,"lon":31},{"facility":15,"status":7,"city":35,"state":7,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":36,"geoPoint":40,"contacts":7},"Ajman",{"type":20,"coordinates":37},[38,39],55.47878,25.40177,{"lat":39,"lon":38},{"facility":15,"status":7,"city":42,"state":7,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":43,"geoPoint":47,"contacts":7},"Dubai",{"type":20,"coordinates":44},[45,46],55.30927,25.07725,{"lat":46,"lon":45},{"type":49,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100270849","real-world-assessment-of-clinical-outcome-changes--including-month-of-ramadan-for-dapagliflozin-in-management-of-type-ii-diabetes-mellitus-100270849",false,"NCT02805361","Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus","Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan- for Dapagliflozin in Management of Type 2 Diabetes Mellitus","REWARD","Inclusion Criteria:\n\nThe target population will be selected according to the following inclusion criteria:\n\n* Males and females participants aged 18 years and older who are diagnosed type 2 Diabetic patients- (Based on American Diabetes Association diagnostic criteria (ADA), The ADA defines diabetes as a fasting blood glucose (FBG) of ≥ 126mg\u002FdL or a 2-hour glucose level post oral glucose tolerance test (OGTT) of ≥ 200 mg\u002FdL or HbAJC of ≥ 6.5%).\n* Patients treated with Dapagliflozin (as per routine care and in compliance with the locally approved prescribing information) for ≥ 4 weeks and ≤ 16 weeks prior to the recruitment date.\n* Patients with CrCl \\> 60 ml\u002Fmin or eGFR \\> 60 ml\u002Fmin\u002F1.73 m2 should be included in trial.\n* Patients providing written informed consent.\n\nExclusion Criteria:\n\n* Patients with contraindications to Dapagliflozin as per the locally approved prescribing information will be excluded from the study.\n* If participating in any clinical trial, the subject cannot take part in this study.\n* Patients with clinically significant renal, hepatic, haematological, oncological, endocrine, psychiatric or rheumatic disease.\n* Patients who don't have a disease with life expectancy under 1 year.\n* Patients with CrCl \\\u003C 60 ml\u002Fmin or eGFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2 should be excluded from the trial.","ALL","18 Years",{"count":61,"type":62},511,"ACTUAL","OBSERVATIONAL","REWARD is an Non Interventional study aims to describe the changes in the clinical outcomes of Type 2 Diabetes Mellitus patients who are treated with Dapagliflozin for a period of one year including the fasting period of Ramadan",[66],"Type II Diabetes Mellitus","COMPLETED","2019-07-12",{"date":70,"type":62},"2019-07-15",{"date":72,"type":62},"2016-08-21",{"date":74,"type":62},"2018-07-13",{"name":5,"class":6},4]